Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cash and Investments: $269.1 million at the end of 2024.Revenue: $29.2 million for Q4 2024; $98.4 million for the full year 2024.R&D Expenses: $28.7 million fo
Mar 12, 2025 / 09:00PM GMTOperator Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference c
Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Qualit
PR NewswireSAN FRANCISCO, Feb. 26, 2025
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com
PR NewswireSAN FRANCISCO and NEW YORK, Feb. 24, 2025
-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study --SAN FRANCISCO and N
On December 31, 2024, Samlyn Capital, LLC executed a notable transaction by acquiring an additional 467,097 shares of Nektar Therapeutics at a trade price of $0
Eventide Asset Management, LLC, a well-regarded investment firm, recently made a significant adjustment to its holdings in Nektar Therapeutics. On December 31,
On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving Nektar Therapeutics (NKTR), reducing its holdings
PR NewswireSAN FRANCISCO, Feb. 10, 2025
SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food
Nektar Therapeutics (NKTR) Monday said that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for its drug candidate rezpegaldesleukin for the treatment of atopic dermatitis in patients aged 12 years and older.
Nektar Therapeutics (NKTR) experienced a significant stock price drop of 5.02%, trading at $0.666 per share with a trading volume of 1.89413 million shares. The
PR NewswireSAN FRANCISCO, Jan. 10, 2025
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com
”“ Vepdegestrant to be combined with Pfizer's novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a se